ASTRA 2025
Hidewaki Nakagawa
Invited Speaker, RIKEN Center
Hidewaki Nakagawa, MD, PhD
Team Leader, Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
Dr. Nakagawa graduated from Osaka University School of Medicine and completed training in clinical oncology of GI cancers as a surgeon. After obtaining his PhD from Osaka University for hereditary cancer genomics, he had postdoctoral training (1999-2003) of cancer genomics and epigenomics at the Human Cancer Genetics Program, The Ohio State University, USA (supervisor Prof. de la Chapelle). In 2003, he returned to Japan as an assistant professor at The University of Tokyo, Institute of Medical Science, where he was dedicated to therapeutic target screening for cancers. In 2008, he moved to RIKEN as a team leader of genomic medicine and his recent research has been focusing on cancer hereditability and cancer genomics by whole genome sequencing for liver cancer, GI cancers, and urological cancers. He has been working for international large-scale cancer genome sequencing project as PIs of PCAWG of ICGC/TCGA. He is now interested in precision cancer medicine and cancer immuno-genomics by single-cell and ST technologies. He has been also dedicated as a member of GA4GH to promote human genome research/medicine and their data sharing and national medical funding system as a program officer of AMED.
Recent papers1. Jikuya R, et al. Comprehensive transcriptome atlas as an assistive modality for complex classification of rare kidney cancers. Nat Commun. in press (2025)
2. Wang H, et al Deep whole genome analysis of 494 hepatocellular carcinomas. Nature. 627(8004):586-593 (2024)
3. Shima Y, Sasagawa S, et al. Increased PDGFRB and NF-κB signaling caused by highly prevalent somatic mutations in intracranial aneurysms. Science Trans Med. 15(700): eabq77218 (2023)
4. Okawa Y, et al. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancers. J Hepatol. 78(2):333-342 (2023)
5. Fujita M, et al. Proteogenomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets. Nat Commun. 13(1):6481 (2022)
6. Sasagawa S, et al. Immuno-genomic profiling of biopsy specimens predicts neoadjuvant chemotherapy response in esophageal squamous cell carcinoma. Cell Rep Med. 3(8):100705 (2022)
7. Nagae G, Yamamoto Y, Fujita M, et al. Genetic and epigenetic basis of hepatoblastoma diversity. Nat Commun. 11(1):5423 (2021)
8. Fujimoto A, et al. Comprehensive analysis of indels in whole-genome microsatellite regions and microsatellite instability across 21 cancer types. Genome Res. 30: 334-346 (2020)
9. The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578(7793):82-93 (2020)
Share with friends
